Cardiovascular safety of evogliptin dual and triple therapy in patients with type 2 diabetes: a nationwide cohort study
Conclusions
These findings suggest that dual or triple therapies of evogliptin for the management of type 2 diabetes in routine clinical practice present no cardiovascular harms, but could alternatively offer cardiovascular benefits in this patient population.
Source: BMJ Open - Category: General Medicine Authors: Park, S., Jeong, H. E., Oh, I.-S., Hong, S., Yu, S. H., Lee, C. B., Shin, J.-Y. Tags: Open access, Diabetes and Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | General Medicine | Health Insurance | Heart | Heart Attack | Heart Failure | Insurance | Metformin | South Korea Health | Study